Chapter 31 - The Ghost in the Consortium

Two years after the Geneva summit and the foundation's permanent debt-free endowment, Hartwell Biosciences had become an untouchable global institution. Yet wealth and open-source philanthropy inevitably destabilize existing power structures. When you eliminate a sixty-billion-dollar pharmaceutical racket by giving cures away at cost, you don’t merely save lives—you create very powerful, very quiet enemies.
It began with an anomaly in the Asian supply line.
Marcus and I were reviewing the regional distribution metrics in our Cambridge executive laboratory. Outside, a gentle spring rain washed over the blooming campus gardens, but inside, the digital terminal displayed an alarming red spike.
"The synthetic enzymatic precursor, Compound K-9," Marcus pointed out, zooming into the Tokyo distribution node. "Shipments destined for our non-profit clinic in Manila have been delayed at the Singapore port of entry for twelve consecutive days. Customs officials cited an unexpected regulatory hold from an international maritime trade syndicate called the Pacific Rim Biosecurity League."
I narrowed my eyes. "The Biosecurity League isn't a government agency, Marcus. It’s an unelected consortium backed by private Swiss and Singaporean hedge funds."
"And look who just joined their executive board last month," Marcus said, clicking open a confidential corporate disclosure file.
A face appeared on the high-definition display. It was Julian’s paternal uncle, Sterling Vale—the reclusive patriarch who had bankrolled Julian’s undergraduate days at Oxford before severing public ties when Julian's father disgraced the family line twenty years ago. Sterling was a ruthless venture capitalist who owned half the deep-water pharmaceutical shipping tankers in East Asia. He had remained completely silent throughout Julian’s arrest, Victoria’s eviction, and Sloane’s downfall.
"Sterling didn't care when Julian went to prison," I observed coldly. "Julian was an embarrassment who got caught. But now our open-source peptide formulation is driving the market capitalization of his specialized shipping fleet down twenty percent per quarter."
My private encrypted phone rang on the desk. The caller ID flashed a name that made me smile despite the tension: Annalise Brooks, calling from her retirement cottage on Martha’s Vineyard.
I answered and put her on speaker. "Annalise, shouldn't you be tending to your hydrangeas?"
"The hydrangeas are boring, Evelyn," Annalise’s gravelly, razor-sharp voice crackled over the line. "And Sterling Vale just made a six-hundred-million-dollar hostile tender offer for our primary raw enzyme supplier in Osaka. He thinks because I’m wearing linen slacks and drinking gin on an island, he can ambush my girl."
May you like
"He's choking our Pacific shipping lanes," I said. "He wants to create an artificial shortage to force us into licensing distribution to his private logistics cartel."
"Then let's teach the older Vale brother the same lesson we taught the younger one," Annalise said with vicious relish. "Pack your bags, Evelyn. We're flying to Tokyo."